Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cidara Therapeutics (CDTX) Gross Profit: 2018-2025

Historic Gross Profit for Cidara Therapeutics (CDTX) over the last 4 years, with Mar 2025 value amounting to -$110,000.

  • Cidara Therapeutics' Gross Profit fell 111.31% to -$110,000 in Q1 2025 from the same period last year, while for Mar 2025 it was $12.3 million, marking a year-over-year decrease of 49.24%. This contributed to the annual value of $1.3 million for FY2024, which is 94.52% down from last year.
  • Latest data reveals that Cidara Therapeutics reported Gross Profit of -$110,000 as of Q1 2025, which was down 136.42% from $302,000 recorded in Q2 2024.
  • In the past 5 years, Cidara Therapeutics' Gross Profit ranged from a high of $40.7 million in Q3 2022 and a low of -$110,000 during Q1 2025.
  • Over the past 3 years, Cidara Therapeutics' median Gross Profit value was $5.1 million (recorded in 2023), while the average stood at $6.3 million.
  • Per our database at Business Quant, Cidara Therapeutics' Gross Profit soared by 868.84% in 2021 and then slumped by 111.31% in 2025.
  • Quarterly analysis of 5 years shows Cidara Therapeutics' Gross Profit stood at $2.8 million in 2021, then soared by 264.96% to $10.2 million in 2022, then grew by 8.62% to $11.1 million in 2023, then tumbled by 94.07% to $302,000 in 2024, then slumped by 111.31% to -$110,000 in 2025.
  • Its last three reported values are -$110,000 in Q1 2025, $302,000 for Q2 2024, and $973,000 during Q1 2024.